Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Ovid Therapeutics (OVID) Research & Development (2020 - 2025)

Ovid Therapeutics (OVID) has disclosed Research & Development for 6 consecutive years, with $5.9 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Research & Development fell 25.27% year-over-year to $5.9 million, compared with a TTM value of $24.9 million through Sep 2025, down 39.9%, and an annual FY2024 reading of $36.8 million, up 28.61% over the prior year.
  • Research & Development was $5.9 million for Q3 2025 at Ovid Therapeutics, down from $6.5 million in the prior quarter.
  • Across five years, Research & Development topped out at $16.2 million in Q1 2021 and bottomed at $4.9 million in Q3 2021.
  • Average Research & Development over 5 years is $7.9 million, with a median of $6.6 million recorded in 2023.
  • The sharpest move saw Research & Development plummeted 69.02% in 2021, then soared 109.73% in 2024.
  • Year by year, Research & Development stood at $12.3 million in 2021, then plummeted by 54.83% to $5.6 million in 2022, then skyrocketed by 91.53% to $10.6 million in 2023, then tumbled by 44.25% to $5.9 million in 2024, then fell by 1.06% to $5.9 million in 2025.
  • Business Quant data shows Research & Development for OVID at $5.9 million in Q3 2025, $6.5 million in Q2 2025, and $6.7 million in Q1 2025.